CB-839 increases glutamine concentration and decreases glutamine metabolites in NSCLC cell lines, with minimal impact on T-cell activation or divisionCB-839 shows synergistic inhibition of tumor growth with anti-PD-1 or anti-PD-L1 inhibition in vivo. The gene discussed is CD274; the disease is neoplasm.